Last 12 months
Inside the activity.
0 purchase rows · 46 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 7 |
| Dec 2025 | 0 | 9 |
| Jan 2026 | 0 | 2 |
| Feb 2026 | 0 | 1 |
| Mar 2026 | 0 | 1 |
| Apr 2026 | 0 | 1 |
| May 2026 | 0 | 2 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 15 |
| Aug 2026 | 0 | 5 |
| Sep 2026 | 0 | 2 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 31, 2026 Filed Aug 4, 2026 20:04 UTC |
Mayes Patrick AEVP & Chief Scientific Officer
|
SaleCommon Stock | 2,187 | $119.47 | $261,280.89 |
DisclosureSEC source: 0002079962-26-000013 · wk-form4_1785873838.xml · nonDerivative · entry 18 Mayes Patrick A · CIK 0002079962 · EVP & Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 81,160 Read SEC document |
| July 31, 2026 Filed Aug 4, 2026 20:04 UTC |
Mayes Patrick AEVP & Chief Scientific Officer
|
SaleCommon Stock | 5,332 | $119.42 | $636,747.44 |
DisclosureSEC source: 0002079962-26-000013 · wk-form4_1785873838.xml · nonDerivative · entry 17 Mayes Patrick A · CIK 0002079962 · EVP & Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 83,347 Read SEC document |
| July 31, 2026 Filed Aug 4, 2026 20:04 UTC |
Mayes Patrick AEVP & Chief Scientific Officer
|
SaleCommon Stock | 14,661 | $119.46 | $1,751,403.06 |
DisclosureSEC source: 0002079962-26-000013 · wk-form4_1785873838.xml · nonDerivative · entry 16 Mayes Patrick A · CIK 0002079962 · EVP & Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 88,679 Read SEC document |
| July 31, 2026 Filed Aug 4, 2026 20:04 UTC |
Mayes Patrick AEVP & Chief Scientific Officer
|
Exercise / conversionCommon Stock | 326 | $105.43 | $34,370.18 |
DisclosureSEC source: 0002079962-26-000013 · wk-form4_1785873838.xml · nonDerivative · entry 15 Mayes Patrick A · CIK 0002079962 · EVP & Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 103,340 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 31, 2026 Filed Aug 4, 2026 20:04 UTC |
Mayes Patrick AEVP & Chief Scientific Officer
|
Exercise / conversionCommon Stock | 85 | $106.47 | $9,049.95 |
DisclosureSEC source: 0002079962-26-000013 · wk-form4_1785873838.xml · nonDerivative · entry 14 Mayes Patrick A · CIK 0002079962 · EVP & Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 103,014 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 31, 2026 Filed Aug 4, 2026 20:04 UTC |
Mayes Patrick AEVP & Chief Scientific Officer
|
Exercise / conversionCommon Stock | 2,293 | $90.56 | $207,654.08 |
DisclosureSEC source: 0002079962-26-000013 · wk-form4_1785873838.xml · nonDerivative · entry 13 Mayes Patrick A · CIK 0002079962 · EVP & Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 102,929 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 31, 2026 Filed Aug 4, 2026 20:04 UTC |
Mayes Patrick AEVP & Chief Scientific Officer
|
Exercise / conversionCommon Stock | 1,642 | $85.01 | $139,586.42 |
DisclosureSEC source: 0002079962-26-000013 · wk-form4_1785873838.xml · nonDerivative · entry 12 Mayes Patrick A · CIK 0002079962 · EVP & Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 100,636 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 31, 2026 Filed Aug 4, 2026 20:04 UTC |
Mayes Patrick AEVP & Chief Scientific Officer
|
Exercise / conversionCommon Stock | 2,623 | $83.58 | $219,230.34 |
DisclosureSEC source: 0002079962-26-000013 · wk-form4_1785873838.xml · nonDerivative · entry 11 Mayes Patrick A · CIK 0002079962 · EVP & Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 98,994 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 31, 2026 Filed Aug 4, 2026 20:04 UTC |
Mayes Patrick AEVP & Chief Scientific Officer
|
Exercise / conversionCommon Stock | 3,023 | $83.20 | $251,513.60 |
DisclosureSEC source: 0002079962-26-000013 · wk-form4_1785873838.xml · nonDerivative · entry 10 Mayes Patrick A · CIK 0002079962 · EVP & Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 96,371 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 31, 2026 Filed Aug 4, 2026 20:04 UTC |
Mayes Patrick AEVP & Chief Scientific Officer
|
Exercise / conversionCommon Stock | 1,643 | $80.50 | $132,261.50 |
DisclosureSEC source: 0002079962-26-000013 · wk-form4_1785873838.xml · nonDerivative · entry 9 Mayes Patrick A · CIK 0002079962 · EVP & Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 93,348 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 31, 2026 Filed Aug 4, 2026 20:04 UTC |
Mayes Patrick AEVP & Chief Scientific Officer
|
Exercise / conversionCommon Stock | 2,864 | $77.67 | $222,446.88 |
DisclosureSEC source: 0002079962-26-000013 · wk-form4_1785873838.xml · nonDerivative · entry 8 Mayes Patrick A · CIK 0002079962 · EVP & Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 91,705 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 31, 2026 Filed Aug 4, 2026 20:04 UTC |
Mayes Patrick AEVP & Chief Scientific Officer
|
Exercise / conversionCommon Stock | 2,623 | $74.78 | $196,147.94 |
DisclosureSEC source: 0002079962-26-000013 · wk-form4_1785873838.xml · nonDerivative · entry 7 Mayes Patrick A · CIK 0002079962 · EVP & Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 88,841 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 31, 2026 Filed Aug 4, 2026 20:04 UTC |
Mayes Patrick AEVP & Chief Scientific Officer
|
Exercise / conversionCommon Stock | 9,459 | $72.27 | $683,601.93 |
DisclosureSEC source: 0002079962-26-000013 · wk-form4_1785873838.xml · nonDerivative · entry 6 Mayes Patrick A · CIK 0002079962 · EVP & Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 86,218 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 31, 2026 Filed Aug 4, 2026 20:04 UTC |
Mayes Patrick AEVP & Chief Scientific Officer
|
Exercise / conversionCommon Stock | 2,072 | $71.93 | $149,038.96 |
DisclosureSEC source: 0002079962-26-000013 · wk-form4_1785873838.xml · nonDerivative · entry 5 Mayes Patrick A · CIK 0002079962 · EVP & Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 76,759 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 31, 2026 Filed Aug 4, 2026 20:04 UTC |
Mayes Patrick AEVP & Chief Scientific Officer
|
Exercise / conversionCommon Stock | 3,148 | $68.62 | $216,015.76 |
DisclosureSEC source: 0002079962-26-000013 · wk-form4_1785873838.xml · nonDerivative · entry 4 Mayes Patrick A · CIK 0002079962 · EVP & Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 74,687 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 31, 2026 Filed Aug 4, 2026 20:04 UTC |
Mayes Patrick AEVP & Chief Scientific Officer
|
Exercise / conversionCommon Stock | 2,709 | $61.76 | $167,307.84 |
DisclosureSEC source: 0002079962-26-000013 · wk-form4_1785873838.xml · nonDerivative · entry 3 Mayes Patrick A · CIK 0002079962 · EVP & Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 71,539 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 31, 2026 Filed Aug 4, 2026 20:04 UTC |
Mayes Patrick AEVP & Chief Scientific Officer
|
Exercise / conversionCommon Stock | 2,284 | $64.25 | $146,747.00 |
DisclosureSEC source: 0002079962-26-000013 · wk-form4_1785873838.xml · nonDerivative · entry 2 Mayes Patrick A · CIK 0002079962 · EVP & Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 68,830 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 31, 2026 Filed Aug 4, 2026 20:04 UTC |
Mayes Patrick AEVP & Chief Scientific Officer
|
Exercise / conversionCommon Stock | 2,918 | $61.18 | $178,523.24 |
DisclosureSEC source: 0002079962-26-000013 · wk-form4_1785873838.xml · nonDerivative · entry 1 Mayes Patrick A · CIK 0002079962 · EVP & Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 66,546 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 23, 2026 Filed Jul 27, 2026 22:23 UTC |
Morrissey Michael JamesEVP, Head of Tech. Operations
|
GrantPerformance Shares · Derivative | 8,999 | $0.00 | $0.00 |
DisclosureSEC source: 0001780915-26-000010 · wk-form4_1785191009.xml · derivative · entry 2 Morrissey Michael James · CIK 0001780915 · EVP, Head of Tech. Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,999 Underlying: Common Stock · 8,999 shares Expires 2029-07-23 F2 · derivative.exercise_price: Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ("TSR") over a three-year performance period beginning on January 1, 2026 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer. F2 · derivative.exercise_date: Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ("TSR") over a three-year performance period beginning on January 1, 2026 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer. Read SEC document |
| July 23, 2026 Filed Jul 27, 2026 22:23 UTC |
Morrissey Michael JamesEVP, Head of Tech. Operations
|
GrantEmployee Stock Option (right to buy) · Derivative | 6,426 | $0.00 Strike: $116.69 | $0.00 |
DisclosureSEC source: 0001780915-26-000010 · wk-form4_1785191009.xml · derivative · entry 1 Morrissey Michael James · CIK 0001780915 · EVP, Head of Tech. Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,426 Underlying: Common Stock · 6,426 shares Expires 2036-07-22 F1 · derivative.exercise_date: The July 23, 2026 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document |
| July 23, 2026 Filed Jul 27, 2026 22:23 UTC |
Heeson LeeEVP, Head of Incyte Intl
|
GrantPerformance Shares · Derivative | 13,498 | $0.00 | $0.00 |
DisclosureSEC source: 0002039219-26-000008 · wk-form4_1785190979.xml · derivative · entry 2 Heeson Lee · CIK 0002039219 · EVP, Head of Incyte Intl 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,498 Underlying: Common Stock · 13,498 shares Expires 2029-07-23 F2 · derivative.exercise_price: Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ("TSR") over a three-year performance period beginning on January 1, 2026 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer. F2 · derivative.exercise_date: Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ("TSR") over a three-year performance period beginning on January 1, 2026 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer. Read SEC document |
| July 23, 2026 Filed Jul 27, 2026 22:23 UTC |
Heeson LeeEVP, Head of Incyte Intl
|
GrantEmployee Stock Option (right to buy) · Derivative | 15,423 | $0.00 Strike: $116.69 | $0.00 |
DisclosureSEC source: 0002039219-26-000008 · wk-form4_1785190979.xml · derivative · entry 1 Heeson Lee · CIK 0002039219 · EVP, Head of Incyte Intl 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,423 Underlying: Common Stock · 15,423 shares Expires 2036-07-22 F1 · derivative.exercise_date: The July 23, 2026 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document |
| July 16, 2026 Filed Jul 20, 2026 20:10 UTC |
Tray ThomasPrincipal Accounting Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 4,079 | $0.00 Strike: $116.65 | $0.00 |
DisclosureSEC source: 0001912317-26-000015 · wk-form4_1784578233.xml · derivative · entry 2 Tray Thomas · CIK 0001912317 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,079 Underlying: Common Stock · 4,079 shares Expires 2036-07-15 F3 · derivative.exercise_date: The July 16, 2026 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Remarks: Read SEC document |
| July 16, 2026 Filed Jul 20, 2026 20:10 UTC |
Tray ThomasPrincipal Accounting Officer
|
GrantCommon Stock | 2,834 | $0.00 | $0.00 |
DisclosureSEC source: 0001912317-26-000015 · wk-form4_1784578233.xml · nonDerivative · entry 1 Tray Thomas · CIK 0001912317 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,699 F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years. The RSUs may be settled only for shares of common stock on a one-for-one basis. F2 · balance_after: Including the July 16, 2026 grant, this includes an aggregate of 13,070 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| July 16, 2026 Filed Jul 20, 2026 20:10 UTC |
Stein Steven HCMO & Head of Late-Stage Dev.
|
GrantEmployee Stock Option (right to buy) · Derivative | 42,298 | $0.00 Strike: $116.65 | $0.00 |
DisclosureSEC source: 0001673776-26-000019 · wk-form4_1784578217.xml · derivative · entry 4 Stein Steven H · CIK 0001673776 · CMO & Head of Late-Stage Dev. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,298 Underlying: Common Stock · 42,298 shares Expires 2036-07-15 F4 · derivative.exercise_date: The July 16, 2026 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Remarks: Read SEC document |
| July 16, 2026 Filed Jul 20, 2026 20:10 UTC |
Stein Steven HCMO & Head of Late-Stage Dev.
|
GrantPerformance Shares · Derivative | 24,496 | $0.00 | $0.00 |
DisclosureSEC source: 0001673776-26-000019 · wk-form4_1784578217.xml · derivative · entry 3 Stein Steven H · CIK 0001673776 · CMO & Head of Late-Stage Dev. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,496 Underlying: Common Stock · 24,496 shares Expires 2029-07-16 F3 · derivative.exercise_price: Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ("TSR") over a three-year performance period beginning on January 1, 2026 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer. F3 · derivative.exercise_date: Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ("TSR") over a three-year performance period beginning on January 1, 2026 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer. Read SEC document |
| July 16, 2026 Filed Jul 20, 2026 20:10 UTC |
Stein Steven HCMO & Head of Late-Stage Dev.
|
GrantCommon Stock | 9,798 | $0.00 | $0.00 |
DisclosureSEC source: 0001673776-26-000019 · wk-form4_1784578217.xml · nonDerivative · entry 2 Stein Steven H · CIK 0001673776 · CMO & Head of Late-Stage Dev. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,916 F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years. The RSUs may be settled only for shares of common stock on a one-for-one basis. F2 · balance_after: Including the July 16, 2026 grant, this includes an aggregate of 29,338 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| July 16, 2026 Filed Jul 20, 2026 20:10 UTC |
Stein Steven HCMO & Head of Late-Stage Dev.
|
SaleCommon Stock | 1,877 | $114.73 | $215,348.21 |
DisclosureSEC source: 0001673776-26-000019 · wk-form4_1784578217.xml · nonDerivative · entry 1 Stein Steven H · CIK 0001673776 · CMO & Head of Late-Stage Dev. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,118 Read SEC document |
| July 16, 2026 Filed Jul 20, 2026 20:10 UTC |
Mayes Patrick AEVP & Chief Scientific Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 25,538 | $0.00 Strike: $116.65 | $0.00 |
DisclosureSEC source: 0002079962-26-000011 · wk-form4_1784578199.xml · derivative · entry 3 Mayes Patrick A · CIK 0002079962 · EVP & Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,538 Underlying: Common Stock · 25,538 shares Expires 2036-07-15 F4 · derivative.exercise_date: The July 16, 2026 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Remarks: Read SEC document |
| July 16, 2026 Filed Jul 20, 2026 20:10 UTC |
Mayes Patrick AEVP & Chief Scientific Officer
|
GrantPerformance Shares · Derivative | 14,790 | $0.00 | $0.00 |
DisclosureSEC source: 0002079962-26-000011 · wk-form4_1784578199.xml · derivative · entry 2 Mayes Patrick A · CIK 0002079962 · EVP & Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,790 Underlying: Common Stock · 14,790 shares Expires 2029-07-16 F3 · derivative.exercise_price: Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ("TSR") over a three-year performance period beginning on January 1, 2026 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer. F3 · derivative.exercise_date: Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ("TSR") over a three-year performance period beginning on January 1, 2026 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer. Read SEC document |
| July 16, 2026 Filed Jul 20, 2026 20:10 UTC |
Mayes Patrick AEVP & Chief Scientific Officer
|
GrantCommon Stock | 5,916 | $0.00 | $0.00 |
DisclosureSEC source: 0002079962-26-000011 · wk-form4_1784578199.xml · nonDerivative · entry 1 Mayes Patrick A · CIK 0002079962 · EVP & Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,628 F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years. The RSUs may be settled only for shares of common stock on a one-for-one basis. F2 · balance_after: Including the July 16, 2026 grant, this includes an aggregate of 74,327 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| July 16, 2026 Filed Jul 20, 2026 20:09 UTC |
CAGNONI PABLO JPresident, Global Head of R&D
|
GrantEmployee Stock Option (right to buy) · Derivative | 57,861 | $0.00 Strike: $116.65 | $0.00 |
DisclosureSEC source: 0001205703-26-000021 · wk-form4_1784578174.xml · derivative · entry 3 CAGNONI PABLO J · CIK 0001205703 · President, Global Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,861 Underlying: Common Stock · 57,861 shares Expires 2036-07-15 F4 · derivative.exercise_date: The July 16, 2026 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Remarks: Read SEC document |
| July 16, 2026 Filed Jul 20, 2026 20:09 UTC |
CAGNONI PABLO JPresident, Global Head of R&D
|
GrantPerformance Shares · Derivative | 33,508 | $0.00 | $0.00 |
DisclosureSEC source: 0001205703-26-000021 · wk-form4_1784578174.xml · derivative · entry 2 CAGNONI PABLO J · CIK 0001205703 · President, Global Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,508 Underlying: Common Stock · 33,508 shares Expires 2029-07-16 F3 · derivative.exercise_price: Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ("TSR") over a three-year performance period beginning on January 1, 2026 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer. F3 · derivative.exercise_date: Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ("TSR") over a three-year performance period beginning on January 1, 2026 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer. Read SEC document |
| July 16, 2026 Filed Jul 20, 2026 20:09 UTC |
CAGNONI PABLO JPresident, Global Head of R&D
|
GrantCommon Stock | 13,403 | $0.00 | $0.00 |
DisclosureSEC source: 0001205703-26-000021 · wk-form4_1784578174.xml · nonDerivative · entry 1 CAGNONI PABLO J · CIK 0001205703 · President, Global Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 231,332 F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years. The RSUs may be settled only for shares of common stock on a one-for-one basis. F2 · balance_after: Including the July 16, 2026 grant, this includes an aggregate of 183,200 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| July 16, 2026 Filed Jul 20, 2026 20:09 UTC |
Issa Mohamed KhairieEVP, Head of U.S. Commercial
|
GrantEmployee Stock Option (right to buy) · Derivative | 33,918 | $0.00 Strike: $116.65 | $0.00 |
DisclosureSEC source: 0002050035-26-000011 · wk-form4_1784578149.xml · derivative · entry 4 Issa Mohamed Khairie · CIK 0002050035 · EVP, Head of U.S. Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,918 Underlying: Common Stock · 33,918 shares Expires 2036-07-15 F4 · derivative.exercise_date: The July 16, 2026 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Remarks: Read SEC document |
| July 16, 2026 Filed Jul 20, 2026 20:09 UTC |
Issa Mohamed KhairieEVP, Head of U.S. Commercial
|
GrantPerformance Shares · Derivative | 19,643 | $0.00 | $0.00 |
DisclosureSEC source: 0002050035-26-000011 · wk-form4_1784578149.xml · derivative · entry 3 Issa Mohamed Khairie · CIK 0002050035 · EVP, Head of U.S. Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,643 Underlying: Common Stock · 19,643 shares Expires 2029-07-16 F3 · derivative.exercise_price: Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ("TSR") over a three-year performance period beginning on January 1, 2026 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer. F3 · derivative.exercise_date: Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ("TSR") over a three-year performance period beginning on January 1, 2026 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer. Read SEC document |
| July 16, 2026 Filed Jul 20, 2026 20:09 UTC |
Issa Mohamed KhairieEVP, Head of U.S. Commercial
|
GrantCommon Stock | 7,857 | $0.00 | $0.00 |
DisclosureSEC source: 0002050035-26-000011 · wk-form4_1784578149.xml · nonDerivative · entry 2 Issa Mohamed Khairie · CIK 0002050035 · EVP, Head of U.S. Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 71,797 F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years. The RSUs may be settled only for shares of common stock on a one-for-one basis. F2 · balance_after: Including the July 16, 2026 grant, this includes an aggregate of 71,797 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| July 16, 2026 Filed Jul 20, 2026 20:09 UTC |
Issa Mohamed KhairieEVP, Head of U.S. Commercial
|
SaleCommon Stock | 1,093 | $115.01 | $125,705.93 |
DisclosureSEC source: 0002050035-26-000011 · wk-form4_1784578149.xml · nonDerivative · entry 1 Issa Mohamed Khairie · CIK 0002050035 · EVP, Head of U.S. Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 63,940 Read SEC document |
| July 16, 2026 Filed Jul 20, 2026 20:08 UTC |
Basi Ramitpal KEVP, Human Resources
|
GrantEmployee Stock Option (right to buy) · Derivative | 21,548 | $0.00 Strike: $116.65 | $0.00 |
DisclosureSEC source: 0002083591-26-000005 · wk-form4_1784578131.xml · derivative · entry 3 Basi Ramitpal K · CIK 0002083591 · EVP, Human Resources 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,548 Underlying: Common Stock · 21,548 shares Expires 2036-07-15 F4 · derivative.exercise_date: The July 16, 2026 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Remarks: Read SEC document |
| July 16, 2026 Filed Jul 20, 2026 20:08 UTC |
Basi Ramitpal KEVP, Human Resources
|
GrantPerformance Shares · Derivative | 12,479 | $0.00 | $0.00 |
DisclosureSEC source: 0002083591-26-000005 · wk-form4_1784578131.xml · derivative · entry 2 Basi Ramitpal K · CIK 0002083591 · EVP, Human Resources 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,479 Underlying: Common Stock · 12,479 shares Expires 2029-07-16 F3 · derivative.exercise_price: Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ("TSR") over a three-year performance period beginning on January 1, 2026 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer. F3 · derivative.exercise_date: Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ("TSR") over a three-year performance period beginning on January 1, 2026 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer. Read SEC document |
| July 16, 2026 Filed Jul 20, 2026 20:08 UTC |
Basi Ramitpal KEVP, Human Resources
|
GrantCommon Stock | 4,991 | $0.00 | $0.00 |
DisclosureSEC source: 0002083591-26-000005 · wk-form4_1784578131.xml · nonDerivative · entry 1 Basi Ramitpal K · CIK 0002083591 · EVP, Human Resources 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,497 F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years. The RSUs may be settled only for shares of common stock on a one-for-one basis. F2 · balance_after: Including the July 16, 2026 grant, this includes an aggregate of 11,497 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| July 16, 2026 Filed Jul 20, 2026 20:08 UTC |
Gardner David HEVP, Chief Strategy Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 31,923 | $0.00 Strike: $116.65 | $0.00 |
DisclosureSEC source: 0002085970-26-000005 · wk-form4_1784578107.xml · derivative · entry 3 Gardner David H · CIK 0002085970 · EVP, Chief Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,923 Underlying: Common Stock · 31,923 shares Expires 2036-07-15 F4 · derivative.exercise_date: The July 16, 2026 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Remarks: Read SEC document |
| July 16, 2026 Filed Jul 20, 2026 20:08 UTC |
Gardner David HEVP, Chief Strategy Officer
|
GrantPerformance Shares · Derivative | 18,487 | $0.00 | $0.00 |
DisclosureSEC source: 0002085970-26-000005 · wk-form4_1784578107.xml · derivative · entry 2 Gardner David H · CIK 0002085970 · EVP, Chief Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,487 Underlying: Common Stock · 18,487 shares Expires 2029-07-16 F3 · derivative.exercise_price: Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ("TSR") over a three-year performance period beginning on January 1, 2026 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer. F3 · derivative.exercise_date: Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ("TSR") over a three-year performance period beginning on January 1, 2026 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer. Read SEC document |
| July 16, 2026 Filed Jul 20, 2026 20:08 UTC |
Gardner David HEVP, Chief Strategy Officer
|
GrantCommon Stock | 7,395 | $0.00 | $0.00 |
DisclosureSEC source: 0002085970-26-000005 · wk-form4_1784578107.xml · nonDerivative · entry 1 Gardner David H · CIK 0002085970 · EVP, Chief Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,824 F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years. The RSUs may be settled only for shares of common stock on a one-for-one basis. F2 · balance_after: Including the July 16, 2026 grant, this includes an aggregate of 16,824 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| July 16, 2026 Filed Jul 20, 2026 20:08 UTC |
Hoffman Richard A.EVP & General Counsel
|
GrantEmployee Stock Option (right to buy) · Derivative | 31,923 | $0.00 Strike: $116.65 | $0.00 |
DisclosureSEC source: 0002098091-26-000005 · wk-form4_1784578078.xml · derivative · entry 3 Hoffman Richard A. · CIK 0002098091 · EVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,923 Underlying: Common Stock · 31,923 shares Expires 2036-07-15 F4 · derivative.exercise_date: The July 16, 2026 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Remarks: Read SEC document |
| July 16, 2026 Filed Jul 20, 2026 20:08 UTC |
Hoffman Richard A.EVP & General Counsel
|
GrantPerformance Shares · Derivative | 18,487 | $0.00 | $0.00 |
DisclosureSEC source: 0002098091-26-000005 · wk-form4_1784578078.xml · derivative · entry 2 Hoffman Richard A. · CIK 0002098091 · EVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,487 Underlying: Common Stock · 18,487 shares Expires 2029-07-16 F3 · derivative.exercise_price: Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ("TSR") over a three-year performance period beginning on January 1, 2026 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer. F3 · derivative.exercise_date: Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ("TSR") over a three-year performance period beginning on January 1, 2026 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer. Read SEC document |
| July 16, 2026 Filed Jul 20, 2026 20:08 UTC |
Hoffman Richard A.EVP & General Counsel
|
GrantCommon Stock | 7,395 | $0.00 | $0.00 |
DisclosureSEC source: 0002098091-26-000005 · wk-form4_1784578078.xml · nonDerivative · entry 1 Hoffman Richard A. · CIK 0002098091 · EVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,861 F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years. The RSUs may be settled only for shares of common stock on a one-for-one basis. F2 · balance_after: Including the July 16, 2026 grant, this includes an aggregate of 16,861 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| July 16, 2026 Filed Jul 20, 2026 20:07 UTC |
Meury WilliamDirector · Chief Executive Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 77,148 | $0.00 Strike: $116.65 | $0.00 |
DisclosureSEC source: 0001536778-26-000009 · wk-form4_1784578056.xml · derivative · entry 3 Meury William · CIK 0001536778 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,148 Underlying: Common Stock · 77,148 shares Expires 2036-07-15 F4 · derivative.exercise_date: The July 16, 2026 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Remarks: Read SEC document |
| July 16, 2026 Filed Jul 20, 2026 20:07 UTC |
Meury WilliamDirector · Chief Executive Officer
|
GrantPerformance Shares · Derivative | 80,421 | $0.00 | $0.00 |
DisclosureSEC source: 0001536778-26-000009 · wk-form4_1784578056.xml · derivative · entry 2 Meury William · CIK 0001536778 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,421 Underlying: Common Stock · 80,421 shares Expires 2029-07-16 F3 · derivative.exercise_price: Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ("TSR") over a three-year performance period beginning on January 1, 2026 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer. F3 · derivative.exercise_date: Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ("TSR") over a three-year performance period beginning on January 1, 2026 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer. Read SEC document |
| July 16, 2026 Filed Jul 20, 2026 20:07 UTC |
Meury WilliamDirector · Chief Executive Officer
|
GrantCommon Stock | 26,807 | $0.00 | $0.00 |
DisclosureSEC source: 0001536778-26-000009 · wk-form4_1784578056.xml · nonDerivative · entry 1 Meury William · CIK 0001536778 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 183,129 F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years. The RSUs may be settled only for shares of common stock on a one-for-one basis. F2 · balance_after: Including the July 16, 2026 grant, this includes an aggregate of 178,883 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.